Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Our purpose is to demonstrate the relationship between microvessel density (MVD), vascular cuffing (VC), vascular endothelial growth factor (VEGF) expression and clinicopathological parameters in ovarian cancer. Surgical specimens from 105 primary ovarian cancers were examined for vascularization and VEGF expression by immunohistochemical staining. The higher MVD group (MVD> or =70) and the positive VEGF group were associated with better progression-free survival only in early stages. The significant association of the MVD with better progression-free survival was recognized only in the patients with clear cell adenocarcinomas. The complete VC group showed a similar trend as MVD though there was no statistical difference. A multivariate analysis revealed MVD to correlate independently with progression-free survival. In ovarian carcinoma, MVD was found to be an independent prognostic factor. In addition, the higher MVD with clear cell adenocarcinoma had the better prognosis. The clinicopathological role of angiogenesis should be analyzed taking account of histologic type.
Ogawa
Shinji
S
Department of Obstetrics and Gynecology, Fukuoka Teishin Hospital, Yakuin 2-6-11, Chuou-ku, Fukuoka 810-8798, Japan. shogawa@gynob.med.kyushu-u.ac.jp
Kaku
Tsunehisa
T
Kobayashi
Hiroaki
H
Hirakawa
Toshio
T
Ohishi
Yoshihiro
Y
Kinukawa
Naoko
N
Nakano
Hitoo
H
D018262:Adenocarcinoma, Clear Cell / Q000098:blood supply* / Q000175:diagnosis / Q000378:metabolism*; D000328:Adult; D000368:Aged; D018450:Disease Progression; D018572:Disease-Free Survival; D016228:Endothelial Growth Factors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008222:Lymphokines / Q000096:biosynthesis*; D008833:Microcirculation; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000175:diagnosis / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors